The USFDA has approved the first immunotherapy drug for breast cancer. Swiss drugmaker Roches Tecentriq was OKd Friday for treating advanced triplenegative breast cancer which accounts for about 15 percent of cases. httpswww.washingtonpost.co

The @US_FDA has approved the first immunotherapy drug for breast cancer. Swiss drugmaker Roche’s Tecentriq was OK’d Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. https://www.washingtonpost.co

The @US_FDA has approved the first immunotherapy drug for breast cancer. Swiss drugmaker Roche’s Tecentriq was OK’d Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. https://www.washingtonpost.com/national/health-science/fda-approves-1st-immunotherapy-drug-to-treat-breast-cancer/2019/03/08/1f0b8696-41fa-11e9-85ad-779ef05fd9d8_story.html …

More From BioPortfolio on "The @US_FDA has approved the first immunotherapy drug for breast cancer. Swiss drugmaker Roche’s Tecentriq was OK’d Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. https://www.washingtonpost.co"